Spyre Therapeutics (SYRE) catalysts

Upcoming FDA decisions and readouts we track for Spyre Therapeutics, each with the filing that announced it.

Listed on — Nasdaq Catalysts tracked — 4 Rows last checked — 14 Sep 2026

FreeBioList tracks 4 catalysts for Spyre Therapeutics (SYRE, listed on Nasdaq): 2 upcoming and 2 decided. They cover 2 programmes: SPY003 (Ulcerative colitis) and SPY072 (Rheumatoid arthritis; Psoriatic arthritis; Axial spondyloarthritis).

First on the list: the Phase 2 readout for SPY072 (Psoriatic arthritis), guided by the company to Q4 2026. By stage, the upcoming rows are 2 Phase 2 readouts.

Decided and on record:

SPY003, Phase 2 readout: Positive topline, announced 8 September 2026.
SPY072, Phase 2 readout: Reported 25 August 2026.

Each outcome links to the filing or notice that reported it in the table below.

All 4 rows link to SEC filings (8-K or 6-K). All have been verified by a person reading the filing itself, most recently on 14 Sep 2026. The methodology page explains each status.

Background reading: Clinical trial phases explained: Phase 1 to Phase 4.

Ticker: SYRE
Next catalyst: Q4 2026
Type: Phase 2 readout
Listed options: Yes

Company ▾	Drug ▾	Effect / indication	Next catalyst ▾	Phase / type ▾	Status ▾	Source	Options
Spyre Therapeutics SYRE · Nasdaq	SPY003	Ulcerative colitis	Sep 2026 company guidance	Phase 2 readout	Verified	8-K ↗	Yes
Notes — Filing reports positive Phase 2 SKYLINE Part A topline data for SPY003 in ulcerative colitis; company advancing to SKYLINE Part B combination therapy. Outcome — Positive topline, announced 8 September 2026 — Phase 2 SKYLINE Part A met its primary endpoint with a 10.0-point placebo-adjusted reduction in Robarts Histopathology Index (p<0.0001); clinical remission 20%, endoscopic improvement 30%. Advancing to SKYLINE Part B (combination therapy). Source: 8-K, filed 08 Sep 2026 · verified 14 Sep 2026
Spyre Therapeutics SYRE · Nasdaq	SPY072	Rheumatoid arthritis	Sep 2026 company guidance	Phase 2 readout	Verified	8-K ↗	Yes
Notes — Filing reports SKYWAY RA sub-study results for SPY072: statistically significant improvement vs placebo on DAS28-CRP and ACR20, but effect size insufficient to advance as RA monotherapy. Outcome — Reported 25 August 2026 — both doses beat placebo on primary/secondary endpoints in the SKYWAY RA sub-study, but the effect size did not clear Spyre's internal bar to advance SPY072 as RA monotherapy; the company will explore combination approaches or other indications instead. Source: 8-K, filed 25 Aug 2026 · verified 14 Sep 2026
Spyre Therapeutics SYRE · Nasdaq	SPY072	Psoriatic arthritis	Q4 2026 company guidance	Phase 2 readout	Verified	8-K exhibit 99.1 ↗	Yes
Notes — Filing states: "Topline proof-of-concept data are expected in the fourth quarter of 2026." Source: 8-K exhibit 99.1, filed 04 Aug 2026 · verified 11 Sep 2026
Spyre Therapeutics SYRE · Nasdaq	SPY072	Axial spondyloarthritis	Q4 2026 company guidance	Phase 2 readout	Verified	8-K exhibit 99.1 ↗	Yes
Notes — Filing states: "Topline proof-of-concept data are expected in the fourth quarter of 2026." Source: 8-K exhibit 99.1, filed 04 Aug 2026 · verified 11 Sep 2026

Companies working on related conditions

Xencor (XNCR)Rheumatoid arthritis (CD20 x CD3); B-cell autoimmune disease (CD19 x CD3); Advanced clear cell renal cell carcinoma (ENPP3 x CD3); Ulcerative colitis (anti-TL1A
Jade Biosciences (JBIO)IgA nephropathy (APRIL antibody); Rheumatoid arthritis; Dermatomyositis
Roivant Sciences (ROIV)Non-infectious uveitis; Cutaneous lupus erythematosus; Pulmonary hypertension with interstitial lung disease; Difficult-to-treat rheumatoid arthritis; Graves’ d

Also due in Q4 2026

Zura Bio (ZURA)Phase 2 readout for Tibulizumab (ZB-106), Q4 2026
PMV Pharmaceuticals (PMVP)Phase 2 readout for Rezatapopt, Q4 2026
Structure Therapeutics (GPCR)Phase 2 readout for Aleniglipron, Q4 2026
Arcturus Therapeutics (ARCT)Phase 2 readout for ARCT-032, Q4 2026
Rapport Therapeutics (RAPP)Phase 2 readout for RAP-219, Oct 2026
Jasper Therapeutics (JSPR)Phase 2 readout for KP-104, Q4 2026